进展期非酒精性脂肪性肝病的识别和临床管理路径

摘要/Abstract

摘要： 非酒精性脂肪性肝病(NAFLD)全球流行率达30%~40%,特别是患有2型糖尿病、肥胖和心血管疾病的患者,发生NAFLD的风险尤其高,已成为最常见的慢性肝病。NAFLD患者可进展为肝硬化、肝癌。 NAFLD患者的绝对数量巨大,疾病负担重,然而在基层医疗和糖尿病管理机构中,NAFLD患者进展性肝病风险的识别仍然非常不理想。本文总结一种对NAFLD患者进行危险分层的方法,这将有助于医务工作者对NAFLD患者的管理。

关键词: 非酒精性脂肪性肝病, 危险分层, 进展性肝病, 无创检查, 基层医疗

臧馨雅, 姜绍文, 谢青. 进展期非酒精性脂肪性肝病的识别和临床管理路径[J]. 肝脏, 2023, 28(12): 1395-1398.

参考文献

[1] Chalasani N, Younossi Z, Lavine JE, et al. The diagnosis and management of nonalcoholic fatty liver disease: Practice guidance from the American Association for the Study of Liver Diseases[J]. Hepatology, 2018,67:328-357.
[2] Younossi ZM, Golabi P, Paik JM, et al. The global epidemiology of nonalcoholic fatty liver disease (NAFLD) and nonalcoholic steatohepatitis (NASH): a systematic review[J]. Hepatology,2023,77:1335-1347.
[3] Golabi P, Otgonsuren M, de Avila L,et al. Components of metabolic syndrome increase the risk of mortality in nonalcoholic fatty liver disease (NAFLD)[J]. Medicine (Baltimore),2018,97:e0214.
[4] Younossi Z, Stepanova M, Ong JP, et al. Nonalcoholic Steatohepatitis Is the Fastest Growing Cause of Hepatocellular Carcinoma in Liver Transplant Candidates[J]. Clin Gastroenterol Hepatol,2019,17:748-755.e3.
[5] Golabi P, Sayiner M, Fazel Y, et al. Current complications and challenges in nonalcoholic steatohepatitis screening and diagnosis[J]. Expert Rev Gastroenterol Hepatol,2016,10:63-71.
[6] Taylor RS, Taylor RJ, Bayliss S,et al. Association Between Fibrosis Stage and Outcomes of Patients With Nonalcoholic Fatty Liver Disease: A Systematic Review and Meta-Analysis[J]. Gastroenterology, 2020,158:1611-1625.e12.
[7] Younossi ZM, Pham H, Felix S, et al. Identification of High-Risk Patients With Nonalcoholic Fatty Liver Disease Using Noninvasive Tests From Primary Care and Endocrinology Real-World Practices[J]. Clin Transl Gastroenterol,2021,12:e00340.
[8] Idilman IS, Keskin O, Celik A, et al. A comparison of liver fat content as determined by magnetic resonance imaging-proton density fat fraction and MRS versus liver histology in non-alcoholic fatty liver disease[J]. Acta Radiol,2016,57:271-278.
[9] Afdhal NH. Fibroscan (Transient Elastography) for the Measurement of Liver Fibrosis[J]. Gastroenterol Hepatol,2012,8:605-607.
[10] Kim DW, Park C, Yoon HM, et al. Technical performance of shear wave elastography for measuring liver stiffness in pediatric and adolescent patients: a systematic review and meta-analysis[J]. Eur Radiol, 2019,29:2560-2572.
[11] Yoshioka K, Hashimoto S, Kawabe N. Measurement of liver stiffness as a non-invasive method for diagnosis of non-alcoholic fatty liver disease[J]. Hepatol Res,2015,45:142-151.
[12] Loomba R, Wolfson T, Ang B, et al. Magnetic Resonance Elastography Predicts Advanced Fibrosis in Patients With Nonalcoholic Fatty Liver Disease: A Prospective Study[J]. Hepatology,2014,60:1920-1928.
[13] Rossi E, Adams LA, Ching HL, et al. High biological variation of serum hyaluronic acid and Hepascore, a biochemical marker model for the prediction of liver fibrosis[J]. Clin Chem Lab Med,2013,51:1107-1114.
[14] Feldstein AE, Wieckowska A, Lopez AR,et al. Cytokeratin-18 fragment levels as noninvasive biomarkers for nonalcoholic steatohepatitis: a multicenter validation study[J]. Hepatology,2009,50:1072-1078.
[15] Yang M, Xu D, Liu Y,et al. Combined Serum Biomarkers in Non-Invasive Diagnosis of Non-Alcoholic Steatohepatitis[J]. PloS One,2015,10:e0131664.
[16] Bedogni G, Bellentani S, Miglioli L,et al. The Fatty Liver Index: a simple and accurate predictor of hepatic steatosis in the general population[J]. BMC Gastroenterol,2006,6:33.
[17] Lee JH, Kim D, Kim HJ, et al. Hepatic steatosis index: a simple screening tool reflecting nonalcoholic fatty liver disease[J]. Dig Liver Dis,2010,42:503-508.
[18] Otgonsuren M, Estep MJ, Hossain N, et al. Single non-invasive model to diagnose non-alcoholic fatty liver disease (NAFLD) and non-alcoholic steatohepatitis (NASH)[J]. J Gastroenterol Hepatol,2014,29:2006-2013.
[19] Harrison SA, Ratziu V, Boursier J, ,et al. A blood-based biomarker panel (NIS4) for non-invasive diagnosis of non-alcoholic steatohepatitis and liver fibrosis: a prospective derivation and global validation study[J]. Lancet Gastroenterol Hepatol,2020,5:970-985.
[20] Lee TH, Han SH, Yang JD, et al. Prediction of Advanced Fibrosis in Nonalcoholic Fatty Liver Disease: An Enhanced Model of BARD Score[J]. Gut Liver,2013,7:323-328.
[21] Adams LA, George J, Bugianesi E, et al. Complex non-invasive fibrosis models are more accurate than simple models in non-alcoholic fatty liver disease[J]. J Gastroenterol Hepatol,2011,26:1536-1543.
[22] Armstrong MJ, Houlihan DD, Bentham L, et al. Presence and severity of non-alcoholic fatty liver disease in a large prospective primary care cohort[J]. J Hepatol,2012,56:234-240.
[23] Wada T, Zeniya M. Background of the FIB-4 index in Japanese non-alcoholic fatty liver disease[J]. Intern Med Tokyo Jpn,2015,54:127-132.
[24] Younes R, Caviglia GP, Govaere O, et al. Long-term outcomes and predictive ability of non-invasive scoring systems in patients with non-alcoholic fatty liver disease[J]. J Hepatol,2021,75:786-794.
[25] Poynard T, Morra R, Halfon P, et al. Meta-analyses of FibroTest diagnostic value in chronic liver disease[J]. BMC Gastroenterol,2007,7:40.
[26] Arora A, Sharma P. Non-invasive Diagnosis of Fibrosis in Non-alcoholic Fatty Liver Disease[J]. J Clin Exp Hepatol,2012,2:145-155.
[27] Kim BK, Tamaki N, Imajo K,et al. Head-to-head comparison between MEFIB, MAST, and FAST for detecting stage 2 fibrosis or higher among patients with NAFLD[J]. J Hepatol,2022,77:1482-1490.
[28] Loomba R, Huang DQ, Sanyal AJ,et al. Liver stiffness thresholds to predict disease progression and clinical outcomes in bridging fibrosis and cirrhosis[J]. Gut,2023,72:581-589.
[29] Kanwal F, Shubrook JH, Adams LA, et al. Clinical Care Pathway for the Risk Stratification and Management of Patients With Nonalcoholic Fatty Liver Disease[J]. Gastroenterology, 2021,161:1657-1669.